Overlapping molecular signaling of IRX-2 and Ta1 resulting in synergistic biological activity

Click to increase image sizeClick to decrease image size

Declaration of Interest

P. Naylor has served as a consultant to IRX Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper has been published as part of a supplement issue covering the proceedings of the Fifth International Symposium on Thymosins in Health and Disease and is funded by SciClone Pharmaceuticals.